Each mutation was profiled against six ALK TKIs – crizotinib, ceritinib, alectinib (which recently received FDA approval for treating ALK+ NSCLC patients who failed crizotinib [26]), AP26113 (brigatinib; a dual ALK/EGFR inhibitor in phase I/II trials that received FDA breakthrough therapy designation in 2014 [19]), ASP3026 (an ALK TKI in phase I trials [27, 28]) and AZD3463 (a dual ALK/EGFR inhibitor in preclinical development) [19, 29, 30]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.